VJOncology is committed to improving our service to you

EAU 2020 | PREFERE: active surveillance in prostate cancer

VJOncology is committed to improving our service to you

Peter Albers

Peter Albers, MD, University Hospital of Düsseldorf, Düsseldorf, Germany, describes the results of the PREFERE trial (NCT01717677), evaluating active surveillance in low- and early intermediate-risk prostate cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter